Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
Front Oncol
; 12: 958043, 2022.
Article
in En
| MEDLINE
| ID: mdl-35992783
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Diagnostic_studies
Language:
En
Journal:
Front Oncol
Year:
2022
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Suiza